Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
or

Reshape Lifesciences Inc (RSLS)

Reshape Lifesciences Inc (RSLS)
0.4100 x 11 0.4272 x 3
Post-market by (Cboe BZX)
0.4600 +0.0803 (+21.15%) 04/04/25 [NASDAQ]
0.4100 x 11 0.4272 x 3
Post-market 0.4100 -0.0500 (-10.87%) 19:59 ET
Quote Overview for Fri, Apr 4th, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
0.3617
Day High
0.7151
Open 0.3900
Previous Close 0.3797 0.3797
Volume 122,669,008 122,669,008
Avg Vol 23,449,250 23,449,250
Stochastic %K 3.16% 3.16%
Weighted Alpha -90.74 -90.74
5-Day Change +0.0731 (+18.89%) +0.0731 (+18.89%)
52-Week Range 0.3445 - 29.0000 0.3445 - 29.0000
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,520
  • Shares Outstanding, K 3,305
  • Annual Sales, $ 8,680 K
  • Annual Income, $ -11,390 K
  • EBIT $ -8 M
  • EBITDA $ -8 M
  • 60-Month Beta 1.59
  • Price/Sales 0.02
  • Price/Cash Flow N/A
  • Price/Book 0.15
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -11.83
  • Most Recent Earnings $-3.11 on 11/14/24
  • Next Earnings Date 05/21/25
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical Instruments

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/18
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year -1,182.51
  • Growth Rate Est. (year over year) +184.48%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.3445 +33.53%
on 03/31/25
Period Open: 1.0100
3.0500 -84.92%
on 04/01/25
-0.5500 (-54.46%)
since 03/04/25
3-Month
0.3445 +33.53%
on 03/31/25
Period Open: 4.7000
5.1900 -91.14%
on 01/13/25
-4.2400 (-90.21%)
since 01/03/25
52-Week
0.3445 +33.53%
on 03/31/25
Period Open: 9.8716
29.0000 -98.41%
on 05/29/24
-9.4116 (-95.34%)
since 04/04/24

Most Recent Stories

More News
ReShape Lifesciences® Receives Notice of Allowance for U.S. Patent Related to Its Proprietary Diabetes Neuromodulation Technology

RSLS : 0.4600 (+21.15%)
ReShape Lifesciences, Allarity, Exact Sciences, CVS, AbbVie: 5 Health Care Stocks That Led Retail Message Growth Last Week

Speculation over an impending reverse merger, a Phase 2 trial announcement, comments about upcoming cancer screening tests, a Medicare business deal, and an obesity drug partnership sparked buzz among...

CVS : 63.66 (-5.70%)
EXAS : 42.55 (-3.91%)
ABBV : 186.96 (-7.28%)
RSLS : 0.4600 (+21.15%)
ALLR : 0.7911 (-3.70%)
ReShape Lifesciences® Signs Distribution Agreement in Canada With Liaison Medical for its Next-Generation Lap-Band® 2.0 FLEX

RSLS : 0.4600 (+21.15%)
ReShape Lifesciences® Announces Pricing of Upsized $6.0 Million Public Offering

RSLS : 0.4600 (+21.15%)
ReShape Lifesciences® Granted Key International Patent in Israel for Its Proprietary Diabetes Neuromodulation Technology

RSLS : 0.4600 (+21.15%)
ReShape Lifesciences® Provides Update on Merger Agreement With Vyome Therapeutics and Asset Purchase Agreement With Biorad Medisys

RSLS : 0.4600 (+21.15%)
ReShape Lifesciences® Reports Third Quarter Ended September 30, 2024 Financial Results and Provides Corporate Update

RSLS : 0.4600 (+21.15%)
ReShape Lifesciences® to Announce Financial Results for the Third Quarter Ended September 30, 2024, and Provide Corporate Update

RSLS : 0.4600 (+21.15%)
ReShape Lifesciences® Receives Health Canada Approval for its Next-Generation Lap-Band® 2.0 FLEX

RSLS : 0.4600 (+21.15%)
ReShape Lifesciences® Receives NIH Supplementary Grant with the University of Southern California’s Center for Autonomic Nerve Recording and Stimulation Systems (CARSS) to Further Develop Next-Generation Electrodes for ReShape’s Proprietary...

RSLS : 0.4600 (+21.15%)
ReShape Lifesciences™ to Announce Financial Results for the Second Quarter Ended June 30, 2022 and Provide Corporate Update

Conference Call to be Held at 4:30 pm ET on Monday, August 15 , 2022...

RSLS : 0.4600 (+21.15%)
ReShape Lifesciences™ Receives FDA 510(k) Clearance for the GIBI HD™ Calibration Tubes for use in Gastric and Bariatric Procedures

New Calibration Tubes, in Three Sizes, Will Simplify Gastric and Bariatric Procedures Including Laparoscopic Sleeve Gastrectomy, Gastric Bypass and Gastric...

RSLS : 0.4600 (+21.15%)
ReShape Lifesciences Announces Appointment of Paul F. Hickey as President and Chief Executive Officer

SAN CLEMENTE, Calif., July 27, 2022 (GLOBE NEWSWIRE) -- ReShape Lifesciences™ (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health...

RSLS : 0.4600 (+21.15%)
ReShape Lifesciences Enters into Warrant Exercise Transaction for $2.5 Million in Gross Proceeds

SAN CLEMENTE, Calif., June 17, 2022 (GLOBE NEWSWIRE) -- ReShape Lifesciences Inc. (Nasdaq: RSLS), the premier physician-led weight loss and metabolic...

RSLS : 0.4600 (+21.15%)
ReShape Lifesciences and OpenLoop Sign Agreement to Provide Nationwide Virtual Health Services for Weight Loss and Wellness Through reshapecare™

Solution will Provide Physician-Led Virtual Weight Loss Coaching...

RSLS : 0.4600 (+21.15%)
ReShape Lifesciences™ Reports First Quarter 2022 Financial Results and Provides Corporate Update

March 2022 Revenues Exceeded January’s and February’s, Combined, Indicating DTC Campaign and Other Visibility Activities are Driving Significant Demand for...

RSLS : 0.4600 (+21.15%)
ReShape Lifesciences™ Announces Vernon Vincent to be Recognized as the Distinguished Industry Partner at the ASMBS 2022 LEAD Gala and Awards

SAN CLEMENTE, Calif., May 19, 2022 (GLOBE NEWSWIRE) -- ReShape Lifesciences™ (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health...

RSLS : 0.4600 (+21.15%)
ReShape Lifesciences™ to Announce Financial Results for the First Quarter Ended March 31, 2022 and Provide Corporate Update

Webcast to be Held at 8:30 am ET on Monday, May 23, 2022...

RSLS : 0.4600 (+21.15%)
ReShape Lifesciences to Present at the Q2 Investor Summit

Management will also Present to Members of the Philadelphia Securities Association...

RSLS : 0.4600 (+21.15%)
ReShape Lifesciences™ Reports Year Ended 2021 Financial and Operating Results and Provides Corporate Update

Conference Call to be Held at 5:30 pm ET Today...

RSLS : 0.4600 (+21.15%)

Business Summary

ReShape Lifesciences Inc. provides weight-loss solutions. It offers an integrated portfolio of proven products and services which manage and treat obesity and metabolic disease. ReShape Lifesciences Inc., formerly known as Obalon Therapeutics, is based in SAN CLEMENTE, CA.

See More

Key Turning Points

3rd Resistance Point 1.0162
2nd Resistance Point 0.8657
1st Resistance Point 0.6628
Last Price 0.4600
1st Support Level 0.3094
2nd Support Level 0.1589
3rd Support Level N/A

See More

52-Week High 29.0000
Fibonacci 61.8% 18.0536
Fibonacci 50% 14.6722
Fibonacci 38.2% 11.2909
Last Price 0.4600
52-Week Low 0.3445

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Trader's Cheat Sheet: Your Secret Weapon for Smarter Trades